Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$SWRM @ .0134
$SWRM .02 coming fast
$SWRM gap up tomorrow morning in .02-.03
$SFOR = $SWRM
$SWRM penny coming
ARCS @ .016
Dilution stopped run
$WDLF penny land coming
.01
Yes, CareX Blockchain Platform shows in search results on TDA
News coming soon!
Search ICTY on TDA, and read company name :)
04s next
$HRBR @ .24
$HRBR @ .26
u still in here?
$NSPX @ .0212
My .005s lookin dam good :D
Thanks, 1st $GILD connection: Inspyr, like Gilead's Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment.
2nd $GILD connection: Dr. Hislop (Ridgeway Therapeutics CEO/President) served as Vice President of Clinical Development at CV Therapeutics...was acquired by Gilead for $1.4 billion.
*Dr. Hislop (Ridgeway Therapeutics) owns 65mil shares of a 120mil float of $NSPX shares!!!
Indeed and it shows 2 connections w/ $GILD
$NSPX
Colin Hislop, MD
SENIOR VICE PRESIDENT, CLINICAL AND DEVELOPMENT OPERATIONS (EIGER BIOPHARMACEUTICALS)
Colin Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies.
Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics ( $CVTX) where he developed and filed an NDA for Ranexa for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4, and has led numerous US, European, and global regulatory filings, including 4 NDAs.
Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) at the University of London.
EIGER BIOPHARMACEUTICALS
https://www.eigerbio.com/team/
$EIGR
RIDGEWAY THERAPEUTICS PRESIDENT & CEO - owns 65mil $NSPX shares of a 120mil float
https://www.linkedin.com/in/colin-hislop-m-b-b-s-b716905/
Ridgeway Therapeutics CEO: Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics which was acquired by $GILD for $1.4 billion.
$NSPX
Ridgeway Therapeutics owns 65mil shares out of 120mil shares in $NSPX float. Ridgeway Therapeutics CEO: Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa®? for angina. CV Therapeutics was acquired by $GILD for $1.4 billion.
https://theorg.com/org/eiger-biopharmaceuticals/team/colin-hislop
https://www.linkedin.com/in/colin-hislop-m-b-b-s-b716905
$NSPX, like $GILD Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment.
http://web.archive.org/web/20200427204401/https://www.marketwatch.com/press-release/these-companies-are-high-potential-game-changers-for-covid-19-treatments-vaccines-2020-03-27
$NSPX Wikipedia: https://en.m.wikipedia.org/wiki/GenSpera
$NSPX, like $GILD Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment.
$NSPX CEO: Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa® for angina. CV Therapeutics was acquired by Gilead for $1.4 billion.
$NSPX $GILD
Doesn’t go into affect until November 16
$NSPX only 150mil shares authorized and Ridgeway Therapeutics owns 65mil shares of the authorized amount so only 85mil shares authorized available to distribute in float!!!
$NSPX @ .048
$RNWF .005 LOD
$NSPX, like $GILD Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment.
http://web.archive.org/web/20200427204401/https://www.marketwatch.com/press-release/these-companies-are-high-potential-game-changers-for-covid-19-treatments-vaccines-2020-03-27
.10 let’s get it!!!
EPIC .10 coming
$NSPX
$NSPX @ .035
Huge gap up tomorrow AM
Silvertown tomorrow
$NSPX
$NSPX, like $GILD Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment.
http://web.archive.org/web/20200427204401/https://www.marketwatch.com/press-release/these-companies-are-high-potential-game-changers-for-covid-19-treatments-vaccines-2020-03-27
.04+ close baby, gap up tomorrow AM
$NSPX
.04 coming today